Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting

Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting

Abstract Cellular immunotherapy, including the chimeric antigen receptor T (CAR-T) cell therapy and CAR- natural killer (CAR-NK) cell therapy, has undergone extensive clinical investigation and development in recent years. CAR-T cell therapy is now emerging as a powerful cancer therapy with enormous...

Full description

Bibliographic Details
Main Authors:	Ji-nuo Wang, Tianning Gu, Yongxian Hu, He Huang
Format:	Article
Language:	English
Published:	BMC 2022-09-01
Series:	Experimental Hematology & Oncology
Subjects:	Hematological malignancies Cellular immunotherapy The 2021 ASH annual meeting Chimeric antigen receptor (CAR) Induced pluripotent stem cell (iPSC)
Online Access:	https://doi.org/10.1186/s40164-022-00316-8

Similar Items

Dual-targeted CAR T-cell immunotherapies for hematological malignancies: latest updates from the 2023 ASH annual meeting
by: Jingyi Yang, et al.
Published: (2024-02-01)

Harnessing the Power of Induced Pluripotent Stem Cells and Gene Editing Technology: Therapeutic Implications in Hematological Malignancies
by: Ishnoor Sidhu, et al.
Published: (2021-10-01)

Editorial: Immunotherapy for hematological malignancies in children
by: Yusi Zhou, et al.
Published: (2023-10-01)

Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy
by: Shuyi Ding, et al.
Published: (2023-11-01)

Immune cells and RBCs derived from human induced pluripotent stem cells: method, progress, prospective challenges
by: Jin-he Jiang, et al.
Published: (2024-01-01)

Generation of an Alagille syndrome (ALGS) patient-derived induced pluripotent stem cell line (TRNDi032-A) carrying a heterozygous mutation (p.Cys682Leufs*7) in the JAG1 gene
by: Omer Hatim, et al.
Published: (2023-12-01)

Standards for Deriving Nonhuman Primate-Induced Pluripotent Stem Cells, Neural Stem Cells and Dopaminergic Lineage
by: Guang Yang, et al.
Published: (2018-09-01)

Chimeric Antigen Receptor T Cell Therapy in Hematology
by: Pınar Ataca, et al.
Published: (2015-11-01)

Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies
by: Ali Keshavarz, et al.
Published: (2022-09-01)

The American Academy of Health Behavior 2017 Annual Scientific Meeting: "Health Behavior Research in the Age of Personalized Medicine"
by: AAHB Board and 2017 Conference Committee
Published: (2017-10-01)

CAR NK-сells for the treatment of hematological malignancies: A review
by: Irina V. Gribkova
Published: (2022-11-01)

<i>Monodelphis domestica</i> Induced Pluripotent Stem Cells Reveal Metatherian Pluripotency Architecture
by: Satish Kumar, et al.
Published: (2022-10-01)

Targeted protein degradation in hematologic malignancies: latest updates from the 2023 ASH annual meeting
by: Guangcai Zhong, et al.
Published: (2024-03-01)

Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting
by: Jiaxiong Tan, et al.
Published: (2023-07-01)

Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
by: Ji-Yoon Noh, et al.
Published: (2020-10-01)

Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies
by: Bailu Xie, et al.
Published: (2022-06-01)

Disease Modeling of Mitochondrial Cardiomyopathy Using Patient-Specific Induced Pluripotent Stem Cells
by: Takeshi Tokuyama, et al.
Published: (2021-09-01)

Alzheimer’s in a dish – induced pluripotent stem cell-based disease modeling
by: Sherida de Leeuw, et al.
Published: (2019-07-01)

Editorial: Transdetermination, transdifferentiation, and reprogramming of cells: In vitro and in vivo strategies
by: Artur Cieslar-Pobuda, et al.
Published: (2023-04-01)

CAR T-Cell Therapy in Hematological Malignancies
by: Theresa Haslauer, et al.
Published: (2021-08-01)

Genome editing iPSC to purposing enhancement of induce CD8 killer T cell function for regenerative immunotherapy
by: Sota Kurihara, et al.
Published: (2024-04-01)

Polymerized Laminin-521: A Feasible Substrate for Expanding Induced Pluripotent Stem Cells at a Low Protein Concentration
by: Fernanda C. P. Mesquita, et al.
Published: (2022-12-01)

Generation of two induced pluripotent stem cell lines from patients with cardiac amyloidosis carrying heterozygous transthyretin (TTR) mutation
by: Bernardo Bonilauri, et al.
Published: (2023-10-01)

Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy
by: Yang Zhou, et al.
Published: (2022-05-01)

State-of-the-art and annual progress of bridge engineering in 2021
by: Renda Zhao, et al.
Published: (2022-12-01)

Unlocking the Pragmatic Potential of Regenerative Therapies in Heart Failure with Next-Generation Treatments
by: Yoshikazu Kishino, et al.
Published: (2023-03-01)

Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting
by: Wenjie Zhang, et al.
Published: (2024-04-01)

The 47th Annual meeting of the European Association for the Study of Diabetes (EASD), 12-16 September, Lisbon
by: Anatoliy Gennad'evich Kuz'min, et al.
Published: (2011-09-01)

CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity
by: Jing Yuan Tan, et al.
Published: (2022-06-01)

iPSC-Derived Cardiomyocytes in Inherited Cardiac Arrhythmias: Pathomechanistic Discovery and Drug Development
by: Eline Simons, et al.
Published: (2023-01-01)

116th Annual Meeting Medical Library Association, Inc. Toronto, ON, Canada May 13-18, 2016
by: Nicole Mitchell
Published: (2017-01-01)

119th Annual Meeting, Medical Library Association, Inc., Chicago, IL, May 3–8, 2019
by: JJ Pionke, et al.
Published: (2020-01-01)

Impressie van de 61th annual meeting of the Gerontological Society of America
by: Charles G. Willems
Published: (2023-07-01)

122nd Annual Meeting, Medical Library Association, Inc., New Orleans, LA, May 3-6, 2022
by: JJ Pionke, et al.
Published: (2023-04-01)

Integrative Meta-Analysis during Induced Pluripotent Stem Cell Reprogramming Reveals Conserved Networks and Chromatin Accessibility Signatures in Human and Mouse
by: Chloe S. Thangavelu, et al.
Published: (2023-11-01)

Generation of two induced pluripotent stem cell lines from healthy patients of African American ancestry
by: McKay Mullen, et al.
Published: (2024-04-01)

CAR-T cell therapy for hematological malignancies: History, status and promise
by: Chao Wang, et al.
Published: (2023-11-01)

Progress and emerging techniques for biomaterial-based derivation of mesenchymal stem cells (MSCs) from pluripotent stem cells (PSCs)
by: Nityanand Prakash, et al.
Published: (2023-04-01)

Generation of two induced pluripotent stem cell lines (RCMGi005-A/B) from human skin fibroblasts of a cystic fibrosis patient with homozygous F508del mutation in CFTR gene
by: Irina Panchuk, et al.
Published: (2022-10-01)

Induced CAR-Macrophages as a Novel Therapeutic Cell Type for Cancer Immune Cell Therapies
by: Siyu Su, et al.
Published: (2022-05-01)